[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Peking University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":657},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,80,0,25,[9,44,68,96,123,147,175,204,225,252,280,306,329,357,382,405,430,450,474,503,533,554,579,605,631],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100629888","efficacy-and-mechanisms-of-escitalopram-in-drug-nave-first-episode-major-depressive-disorder-100629888",false,"NCT07480525","Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder","Inclusion Criteria:\n\n1. Aged 18-65 years (including 18 and 65), no gender restriction, Han Chinese ethnicity.\n2. Meets the diagnostic criteria for depressive disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), confirmed by the Mini-International Neuropsychiatric Interview, version 5.0 (MINI).\n3. Outpatients or inpatients; Hamilton Depression Rating Scale-17 items (HAMD-17) score ≥17; Hypomania Checklist-32 (HCL-32) score ≤13; and Clinical Global Impressions-Severity (CGI-S) score ≥4.\n4. First depressive episode (duration ≤3 months), with no use of antidepressants or other psychotropic medications in the past 3 months.\n5. Written informed consent obtained from the patient.\n\nExclusion Criteria:\n\n1. Meet DSM-IV diagnostic criteria other mental disorders, including schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, obsessive-compulsive disorder, etc..\n2. Individuals with intellectual disabilities or who are unable to cooperate for other reasons, or those lacking or having incomplete civil capacity during the onset of illness;\n3. Suffering from neurological or organic brain diseases (such as stroke, cerebral hemorrhage, brain tumors, Parkinson's disease, epilepsy, etc.) and a history of severe traumatic brain injury;\n4. Have attempted suicide within the past 3 months, or currently present a high suicide risk, defined as a Montgomery-Åsberg Depression Rating Scale (MADRS) item 10 score ≥5.\n5. Are pregnant or breastfeeding, cannot use reliable contraception during the study, or plan to conceive (or impregnate a partner) within 3 months after study initiation.\n6. Have known allergies to escitalopram oxalate or its excipients.\n7. Are currently taking medications that may interfere with the evaluation of escitalopram efficacy.\n8. Have participated in another drug clinical trial within the past 3 months.\n9. Have contraindications to MRI scanning, such as metal implants or claustrophobia.\n10. Considered unsuitable for study participation by the investigators for any other reason.","ALL","18 Years","65 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this project is to quantify the effectiveness and safety of escitalopram oxalate oral solution in the treatment of first-episode, drug-naïve patients with major depressive disorder, and to explore the mechanisms underlying its antidepressant effects using multi-omics approaches. By integrating clinical, cognitive, laboratory, imaging, genetic, and environmental data, the study aims to identify patient subgroups who are most likely to benefit from escitalopram, thereby promoting individualized and precision treatment for depression.\n\nThis multicenter, prospective, single-arm intervention study will enroll 200 adults aged 18-65 years with major depressive disorder, who will receive escitalopram oxalate oral solution for 8 weeks. Depressive symptoms, cognitive function, and adverse events will be assessed at baseline, during treatment, and after 8 weeks of treatment to evaluate efficacy and safety. Escitalopram blood concentrations will be measured at week 4 to monitor treatment adherence and support safety evaluation. Through comprehensive data collection and multimodal analysis, this project seeks to clarify the biological mechanisms of escitalopram and provide evidence to guide more precise clinical use of antidepressant therapy.",[27],"Depression - Major Depressive Disorder",[29,30],"depression","antidepressant","RECRUITING","2026-08-18",{"date":34,"type":35},"2026-08-20","ACTUAL",{"date":37,"type":35},"2026-03-20",{"date":39,"type":21},"2026-12-31",{"name":41,"class":42},"Peking University","OTHER",5,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100602769","phase-2-assessing-iparomlimab-and-tuvonralimab-in-recurrent-or-metastatic-msi-hdmmr-gastric-cancer-100602769","NCT07127822","Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H\u002FdMMR Gastric Cancer","A Randomized, Controlled, Multi-centers, Non Inferiority Phase II Clinical Study Comparing Iparomlimab and Tuvonralimab With Standard Chemotherapy Combined With PD-1\u002FPD-L1 Monoclonal Antibody as First-line Treatment for MSI-H\u002FdMMR Recurrent\u002FMetastatic Gastric Cancer","Inclusion Criteria:\n\n1\\. Voluntarily willing to participate in the study and sign the written informed consent form 2. Age ≥18 years male or female . 3. Expected survival time ≥ 3 months 4. Patients with unresectable locally advanced, recurrent, or metastatic gastric\u002Fgastroesophageal junction adenocarcinoma diagnosed by histological or cytological examination: 5. Confirmed by PCR or next-generation sequencing(NGS) as microsatellite instability-high(MSI-H) . Patients with mismatch repair defecient identified by immunohistochemistry need to undergo PCR\u002FNGS verification as MSI-H before treatment 6. Patients should not receive systematic anti-tumor treatment before, and for those who have received induction chemotherapy, concurrent radiochemotherapy, or neoadjuvant\u002Fadjuvant chemotherapy for curative purposes, the recurrence time must be at least 6 months from the end of the last treatment; 7. Agree to provide archived tumor tissue specimens or fresh tissue samples of primary or metastatic lesions within 3 years; If the patinet is unable to provide tumor tissue samples, they can be enrolled after evaluation by the researcher, provided that they meet other inclusion and exclusion criteria; 8. Patients must have at least one measurable lesion defined by RECIST 1.1. 9. European Cooperative Oncology Group (ECOG) ≤1 10. No severe cardiac dysfunction, left ventricular ejection fraction ≥ 50%; 11. Patients must meet the following criteria at screening and before preconditioning (baseline). If any laboratory test result is abnormal referring to the following criteria,\n\n1. Hematology: neutrophils (NE) ≥1.5×109 per liter, , platelets (PLT) ≥100×109per liter and hemoglobin (Hb) ≥8.0 g\u002FdL.\n2. Blood chemistry: creatinine clearance ≥50 mL\u002Fmin, Creatinine (Cr) ≤ 1.5 × ULN, alanine aminotransferase (ALT) ≤2.5×ULN（Gilbert syndrome or liver metastasis subjects ≤ 5 × ULN）, aspartate aminotransferase (AST) ≤2.5×ULN（Gilbert syndrome or liver metastasis subjects ≤ 5 × ULN）, total bilirubin (TB) ≤1.5×ULN（Gilbert syndrome or liver metastasis subjects ≤ 3 × ULN）,\n3. International normalized ratio (INR) ≤ 1.5, and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN; 12. Urinary protein ≤ 2+or \\\u003C 1000mg\u002F24h; 13. Women of childbearing potential must have negative serum pregnancy test result at screening and before preconditioning and agree to use an effective and reliable contraceptive method for at least 1 year after the last study treatment. Te acceptable methods include bilateral tubal ligation\u002Fbilateral salpingectomy or bilateral tubal occlusion; any approved oral, injection or implantation of hormone; or barrier contraceptive method: condoms containing spermicidal .\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Previous use of PD-1\u002FPD-L1 monoclonal antibodies, CTLA-4 monoclonal antibodies, or monoclonal and bispecific drugs containing the aforementioned targets;\n3. Existence of any active autoimmune disease or history of autoimmune disease (such as but not limited to: autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis; asthma in which subjects require bronchodilators for medical intervention cannot be included); However, the following diseases are allowed to be included: vitiligo, psoriasis, alopecia without systemic treatment, well controlled type I diabetes, hypothyroidism with normal thyroid function after replacement treatment;\n4. Patients who require immunosuppressive therapy, systemic or absorbable local hormone therapy to achieve immunosuppressive goals (calculated as prednisone, dose\\>10mg\u002Fday or other therapeutic hormones) and continue to use it within 2 weeks of the first administration;\n5. Patients with uncontrolled pleural effusion, pericardial effusion, or ascites that require repeated drainage;\n6. Patients with uncontrollable symptoms of brain metastasis, spinal cord compression, malignant meningitis, or brain or pia mater diseases detected by CT or MRI examination during screening within 4 weeks before the first administration\n7. Patients who have received non systematic anti-tumor therapy within 3 weeks prior to the start of treatment, including but not limited to surgery, radiation therapy, interventional therapy, and anti-tumor traditional Chinese medicine treatment (based on the indications in the Chinese medicine instructions, and may also be enrolled after a 2-week washout period). Patients whose adverse events caused by previous treatment (excluding hair loss) have not recovered to ≤ CTCAE grade 2 are not within the above range;\n8. Patients with any severe and\u002For uncontrolled illnesses, including:\n\n1\\) Patients with poor blood pressure control (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 90 mmHg) 2) Patients who experience unstable angina, myocardial infarction, ≥ grade 2 congestive heart failure, or arrhythmia requiring treatment within 6 months of initial administration (including QTc ≥ 480ms); 3) Active or uncontrolled severe infection (≥ CTCAE grade 2 infection); 4) A history of clinically significant liver disease, including viral hepatitis, known as a carrier of hepatitis B virus (HBV), must exclude active HBV infection, i.e. HBV DNA positive (\\>2000 IU\u002FmL); Known hepatitis C virus infection (HCV) and HCV RNA positivity (\\>1 × 103 copies\u002FmL), or other decompensated liver diseases or chronic hepatitis requiring antiviral therapy; 5) HIV test positive 6) Poor control of diabetes (fasting blood glucose ≥ CTCAE level 2); 9. Patients who have experienced severe infections (CTCAE\\>grade 2) within the first 4 weeks of randomization, such as severe pneumonia, bacteremia, sepsis, tuberculosis, etc; Indications of pulmonary infection or active pulmonary inflammation within the first 2 weeks of randomization; 10. Patients with a history of allergies to recombinant humanized antibodies who are allergic to any excipient components of the drug; 11. History of autologous or allogeneic stem cell transplantation; 12. Patients with a history of serious neurological or psychiatric disorders, including but not limited to: dementia, depression, epileptic seizures, bipolar disorder, etc; 13. Patients diagnosed as active malignant tumor within the first 3 years of randomization, except for the following cases: radical skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ and\u002For radical resection of carcinoma in situ, which the researchers think can be included; 14. Patients who plan to receive live vaccines within 28 days prior to randomization; 15. Researchers evaluate situations where participation in this clinical trial is inappropriate due to complications or other reasons.",{"count":52,"type":21},106,[54],"PHASE2","A randomized controlled phase II study exploring first-line treatment options for recurrent\u002Fmetastatic MSI-H gastric cancer",[57,58],"Gastric \u002F Gastroesophageal Junction Adenocarcinoma","MSI-H Cancer","2026-08-03",{"date":61,"type":35},"2026-08-05",{"date":63,"type":35},"2025-12-15",{"date":65,"type":21},"2028-12-31",{"name":41,"class":42},10,{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":16,"minAge":17,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100649331","a-blood-pressure-lowering-diet-for-preventing-and-managing-hypertension-100649331","NCT07735091","A Blood Pressure-Lowering Diet for Preventing and Managing Hypertension","Translation of a Blood Pressure-Lowering Dietary Pattern for Hypertension Prevention and Control: A Cluster-Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18 to 60 years.\n* Employed by Shengli Oilfield and regularly receiving meals from a participating workplace canteen.\n* Regularly eats at the participating canteen, generally on at least 4 working days per week.\n* Diagnosed with primary hypertension by a qualified medical institution, or meets the diagnostic criterion of systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg on 3 measurements obtained on different days.\n* Hypertension is clinically stable.\n* Antihypertensive medication regimen is stable, when applicable.\n* Able and willing to comply with the dietary intervention, study assessments, and follow-up procedures.\n* Provides written informed consent voluntarily.\n\nExclusion Criteria:\n\n* Secondary hypertension.\n* Pregnancy, breastfeeding, or planning to become pregnant during the study period.\n* Serious food allergy or intolerance to major foods included in the intervention diet, such as nuts, dairy products, or gluten-containing foods.\n* Major cardiovascular or cerebrovascular event within the previous 6 months, such as myocardial infarction or stroke.\n* Severe cardiopulmonary disease, such as heart failure or severe asthma.\n* Cancer, advanced kidney disease, severe liver disease, or another serious medical condition.\n* A medical condition requiring a specialized therapeutic diet that would interfere with the study intervention.\n* Severe psychiatric illness.\n* Severe cognitive impairment that prevents understanding of the informed consent form or compliance with study procedures.\n* Hearing impairment or physical disability that would substantially interfere with participation.\n* Any other condition that, in the judgment of the research team, makes the individual unsuitable for participation.",true,"60 Years",{"count":78,"type":21},800,[24],"This cluster-randomized controlled trial will evaluate whether a 3-month culturally adapted blood pressure-lowering dietary, called the Eastern Blood Pressure-Lowering Diet, can improve blood pressure and related health outcomes in Chinese adults with primary hypertension.\n\nApproximately 800 participants from 16 workplace-based clusters will be assigned to either a standard hypertension management group or a dietary intervention group. Both groups will receive usual hypertension care, including health education and medication treatment when clinically indicated. In addition, participants in the dietary intervention group will receive specially designed weekday lunches, low-sodium salt and reduced-sodium seasonings, and app-based support for dietary recording and adherence monitoring.\n\nThe main outcome is change in resting systolic and diastolic blood pressure. Other outcomes include body weight, waist circumference, body fat, blood glucose, blood lipids, homocysteine, kidney function, estimated 24-hour urinary sodium and potassium excretion, lifestyle behaviors, sleep, psychological well-being, and the occurrence of hypertension-related complications or cardiovascular and cerebrovascular events. Blood, urine, and stool samples will also be analyzed to explore possible metabolic and gut microbiome mechanisms underlying the effects of the dietary intervention.\n\nThe active dietary intervention will last 3 months, and participants will be followed for up to 24 months.",[82],"Hypertension",[84,82,85],"Feeding Trials","Cluster-Randomized Controlled Trial","NOT_YET_RECRUITING","2026-07-26",{"date":89,"type":35},"2026-07-29",{"date":91,"type":21},"2026-08-01",{"date":93,"type":21},"2027-11-01",{"name":41,"class":42},1,{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":95},"100646293","mindfulness-intervention-for-emotional-distress-an-eeg-study-100646293","NCT07692269","Mindfulness Intervention for Emotional Distress: An EEG Study","Effects and Multimodal EEG Mechanisms of an 8-week Mindfulness Intervention for Emotional Distress: A Randomized Controlled Trial","MIED-RCT","Inclusion Criteria:\n\n* Adults aged 18-50 years Kessler Psychological Distress Scale (K10) score \\> 21 No systematic mindfulness or progressive muscle relaxation practice in the past 6 months (frequency \\\u003C 1 time per week) Normal or corrected-to-normal vision Voluntary participation with signed informed consent\n\nExclusion Criteria:\n\n* Prior diagnosis of schizophrenia, bipolar disorder, or other severe mental disorders by a psychiatrist Suicidal plan, self-injury, or need for emergency psychological crisis intervention in the past month Currently receiving systematic psychotherapy or participating in other psychological intervention programs Started psychiatric medication within the past 3 months or on an unstable medication dosage History of epilepsy, severe brain injury, or other neurological disorders that may affect EEG measurement Severe vision or hearing impairment or other conditions preventing completion of study procedures","50 Years",{"count":106,"type":21},160,[24],"This is a randomized controlled trial examining the efficacy and neural mechanisms of a standardized Mindfulness Intervention for Emotional Distress (MIED) in adults with subclinical emotional distress. One hundred and sixty participants will be randomly assigned to either an 8-week MIED program or an 8-week Progressive Muscle Relaxation (PMR) active control. The primary aim is to evaluate whether MIED reduces anxiety symptoms and reshapes multilevel emotional processing as measured by multimodal EEG (resting-state FAA\u002Ftheta, Fast Periodic Visual Stimulation, and event-related potentials). Assessments occur at baseline (T1), post-intervention (T2), and 1-month follow-up.",[110,111,112,113,114],"Emotional Distress","Anxiety","Depression","Stress (Psychology)","Psychological","2026-07-25",{"date":117,"type":35},"2026-07-28",{"date":119,"type":35},"2026-07-04",{"date":121,"type":21},"2027-02",{"name":41,"class":42},{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":104,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":4},"100648774","time-restricted-eating-and-staple-food-reduction-combined-with-app-supported-exercise-for-weight-and-glycemic-control-100648774","NCT07726615","Time-Restricted Eating and Staple Food Reduction Combined With App-Supported Exercise for Weight and Glycemic Control","A Multicenter Randomized Controlled Trial of Time-Restricted Eating, Staple Food Reduction, and App-Supported Exercise for Weight Loss and Glycemic Improvement in Adults With Obesity and Abnormal Glucose Metabolism","TRE-SFR-EX","Inclusion Criteria:\n\n* Age 18 to 50 years, all sexes.\n* Body mass index (BMI) \\>=28 kg\u002Fm2.\n* Willing and able to comply with study procedures and provide written informed consent.\n* Resident living near a participating study site and able to complete scheduled visits.\n* No habitual time-restricted eating or other fasting regimen, such as alternate-day fasting or fasting-mimicking diet.\n* Abnormal glucose metabolism or diabetes, defined as fasting plasma glucose \\>5.6 mmol\u002FL or HbA1c \\>5.7%.\n\nExclusion Criteria:\n\n* Secondary obesity, such as hypothyroidism or Cushing syndrome.\n* Use of weight-loss medication within 90 days before screening, or body weight change \\>5 kg within 90 days before screening.\n* Pregnant, lactating, or planning pregnancy during the study period.\n* Severe cardiac, hepatic, or renal dysfunction.\n* Severe psychiatric disease or cognitive impairment that prevents cooperation with the study.\n* Contraindication to exercise, such as severe osteoarthritis.\n* Unable or unwilling to follow the study diet and exercise intervention.\n* Long-term use of medications that may significantly affect body weight.\n* Active malignancy in any organ system.\n* Any other condition that, in the investigator's judgment, may affect efficacy or safety evaluation or make the participant unsuitable for the study.",{"count":132,"type":21},300,[24],"This multicenter, three-arm randomized controlled trial will evaluate the effects of early time-restricted eating and staple food reduction, each combined with an app-supported exercise intervention, on body weight and glycemic control among adults with obesity and abnormal glucose metabolism. A total of 300 participants aged 18 to 50 years with BMI \\>=28 kg\u002Fm2 and impaired glucose regulation or diabetes will be enrolled at five centers in China and randomized 1:1:1 to app-supported exercise alone, staple food reduction plus app-supported exercise, or early time-restricted eating plus app-supported exercise. The intervention lasts 12 weeks, followed by a 12-week post-intervention follow-up.",[136],"Obesity; Impaired Glucose Regulation; Prediabetes; Type 2 Diabetes Mellitus",[138],"time-restricted eating; staple food reduction; app-supported exercise; obesity; abnormal glucose metabolism; continuous glucose monitoring","2026-07-21",{"date":141,"type":35},"2026-07-24",{"date":143,"type":21},"2026-07",{"date":145,"type":21},"2027-04",{"name":41,"class":42},{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":75,"sex":16,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":163,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":171,"leadSponsor":173,"locationsCount":174},"100647536","effects-of-exercise-sequence-and-meal-sequence-on-weight-management-among-children-and-adolescents-with-overweight-or-obesity-the-step-trial-100647536","NCT07712068","Effects of Exercise Sequence and Meal Sequence on Weight Management Among Children and Adolescents With Overweight or Obesity: The STEP Trial","Inclusion Criteria:\n\nTo be included in the study, participants must be between 10 and 17 years old and have a Body Mass Index equal to or greater than the 95th percentile for their age and sex, which meets the Chinese screening standard for overweight and obesity in school-aged children and adolescents. Additionally, participants and their legal guardians must have signed a service contract and paid in full for the commercial weight loss camp service before signing the study consent form. Participants must possess basic communication skills and the ability to comply with study instructions. They must also pass the mandatory pre-camp exercise risk medical screening, which includes blood and urine tests, blood pressure, resting electrocardiograms, and exercise electrocardiograms. Finally, participants and their legal guardians must provide dual signed informed consent.\n\nExclusion Criteria:\n\nIndividuals are excluded from the study if they have been diagnosed with secondary obesity or genetic obesity syndromes. Furthermore, individuals who have taken medications affecting body weight or bone metabolism within the past three months are not eligible to participate. The study also excludes individuals with clinically diagnosed eating disorders, depression, or other severe psychiatric illnesses. Individuals who are unable or unwilling to cooperate with venous blood sampling or other biological sample collections are excluded as well. Finally, individuals with severe cardiopulmonary dysfunction, severe scoliosis, or other clear medical contraindications to exercise cannot participate in the trial.","10 Years","17 Years",{"count":156,"type":21},480,[24],"The goal of this clinical trial is to learn how the order of exercise and the order of eating food affect weight management in overweight and obese children and adolescents. The main questions it aims to answer are whether doing aerobic or anaerobic exercise first changes weight loss results, and whether eating vegetables and proteins before carbohydrates improves health outcomes compared to a standard diet. Furthermore, the study asks how the exercise order and eating order work together to affect weight and health. Researchers will compare four different groups to see if these specific exercise and eating orders work better to treat obesity. Participants will stay at a closed weight loss camp for 28 days and do daily aerobic and anaerobic exercises in a randomly assigned order. They will eat meals in either a strict order, consuming vegetables and proteins first, or a standard order. Throughout the trial, participants will give blood, urine, stool, saliva, and sweat samples for lab tests, while also checking their body weight, body composition, and heart rate. Finally, they will answer surveys about their diet, physical activity, hunger, and tiredness.",[160,161,162],"Obesity & Overweight","Insulin Resistance","Inflamation",[164,165,166],"child and adolescent obesity","obesity & overweight","child and adolescent insulin resistance","2026-07-13",{"date":169,"type":35},"2026-07-17",{"date":143,"type":21},{"date":172,"type":21},"2026-09-30",{"name":41,"class":42},9,{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":76,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":186,"conditions":187,"keywords":191,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":4},"100642033","phase-4-botulinum-toxin-type-a-injection-sites-for-oral-commissure-ptosis-100642033","NCT07646886","Botulinum Toxin Type A Injection Sites for Oral Commissure Ptosis","Injection Site-Based Multicenter Randomized Controlled Trial: Efficacy and Safety of Focal Botulinum Toxin Type A Injection for Oral Commissure Ptosis","Inclusion Criteria:\n\n* Aged 18 to 60 years, any gender\n* Meet the diagnostic criteria for oral commissure ptosis: bilateral oral commissure ptosis angle (angle between the oral commissure point and the horizontal line of the ipsilateral vermilion border) \\> 1° at rest\n* Have clear aesthetic demand for oral commissure ptosis improvement and can complete full-cycle follow-up\n* No redness, swelling, ulcer, scar, deformity or active infection in the perioral and mental regions\n* Have not participated in other interventional clinical trials within 3 months before enrollment\n\nExclusion Criteria:\n\n* Hypersensitivity to botulinum toxin type A, lidocaine or excipients of injection preparations; or contraindications to botulinum toxin injection (myasthenia gravis, Lambert-Eaton syndrome, motor neuron disease, severe liver and kidney dysfunction, coagulation disorders, uncontrolled autoimmune diseases, malignant tumors)\n* History of mid-lower facial botulinum toxin type A injection, soft tissue filling, laser\u002Fradiofrequency rejuvenation, perioral surgery or orthognathic treatment within 6 months before enrollment\n* Planned perioral treatment within 6 months after enrollment that may affect efficacy evaluation\n* Pregnant or lactating women, or those planning to become pregnant within 6 months\n* Acquired oral commissure ptosis caused by facial nerve palsy\u002Fsequelae, perioral scar traction, severe jaw deformity or severe alveolar bone resorption\n* Severe facial asymmetry (difference in bilateral oral commissure ptosis angle \\> 2°)\n* History of botulinum toxin allergy or severe adverse reactions after previous botulinum toxin injection\n* Currently using aminoglycoside antibiotics, quinine, calcium channel blockers, anticoagulants or other drugs that may affect botulinum toxin efficacy or increase bleeding risk and cannot discontinue\n* History of mental illness, drug\u002Falcohol abuse, or poor compliance unable to complete follow-up\n* Other conditions deemed unsuitable for enrollment by the investigator",{"count":183,"type":21},266,[185],"PHASE4","This multicenter, prospective, randomized parallel-controlled, assessor-blinded clinical trial aims to address the core clinical pain point of lack of high-level evidence and non-standardized operation in injection site selection for BTX-A treatment of oral commissure ptosis. A total of 266 eligible subjects will be randomly assigned in a 1:1 ratio to receive either upper DAO or lower DAO BTX-A injection. The study will compare the clinical efficacy, time-effect characteristics and safety profiles of the two regimens, and conduct stratified analysis of treatment response in different patient subtypes. The results will determine the optimal injection site for Chinese population, establish standardized operation specifications, fill the international evidence gap, and provide level I evidence for clinical practice.",[188,189,190],"Facial Aging","Melomental Folds","Oral Commissure Ptosis",[192,190,189,193,194,195],"Botulinum Toxin Type A","Depressor Anguli Oris Muscle","Randomized Controlled Trial","Injection Site","2026-07-03",{"date":198,"type":35},"2026-07-07",{"date":200,"type":21},"2026-07-01",{"date":202,"type":21},"2027-12-01",{"name":41,"class":42},{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":213,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":224,"locationsCount":4},"100645007","phase-3-retlirafusp-alfa-injection-plus-chemotherapy-versus-investigators-choice-of-anti-pd-1-antibody-plus-chemotherapy-as-first-line-treatment-for-advanced-gastric-cancer-with-liver-metastases-100645007","NCT07677293","Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases","Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy for Previously Untreated, Advanced Gastric or Gastroesophageal Junction Cancer With Liver Metastases: a Randomized, Controlled, Multicenter Phase III Clinical Study","Inclusion Criteria:\n\n* 1\\. Age ≥ 18 years; 2. Patients with recurrent or previously untreated advanced gastric or gastroesophageal junction cancer with liver metastases, histopathologically confirmed as adenocarcinoma.\n\n  3\\. No prior systemic therapy (including anti-HER2 therapy) for advanced or metastatic GC\u002FGEJC. Patients who have received prior adjuvant or neoadjuvant therapy are eligible provided that the time from completion of last therapy to first recurrence or disease progression is \\> 6 months.\n\n  4\\. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 5. At least one evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n\n  6\\. Adequate organ and bone marrow function. 7. Female subjects of non-childbearing potential are defined as those who are postmenopausal, or have undergone documented hysterectomy and\u002For bilateral oophorectomy. Male subjects and female subjects of childbearing potential must agree to use at least one medically approved contraceptive method during the study and for 120 days after the last dose of study treatment. A serum pregnancy test must be negative within 3 days prior to the start of study treatment, and subjects must not be breastfeeding.\n\n  8\\. Voluntarily signed informed consent, and willing and able to comply with scheduled visits, study treatment, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* 1\\. Known gastric cancer of squamous cell carcinoma, undifferentiated carcinoma, or other histological types, or adenocarcinoma mixed with other histological types.\n\n  2\\. Untreated or inadequately treated central nervous system (CNS) metastases, or uncontrolled or symptomatic active CNS metastases.\n\n  3\\. Diagnosis of any other malignancy within 5 years prior to study entry, except for: skin basal cell carcinoma or squamous cell carcinoma that has been locally treated and documented as cured, superficial bladder cancer, cervical carcinoma in situ, breast ductal carcinoma in situ, papillary thyroid carcinoma, and other early-stage tumors with low risk of recurrence that have undergone curative treatment as judged by the investigator.\n\n  4\\. Presence of any active, known, or suspected autoimmune disease. 5. Prior treatment with TGF-β inhibitors, anti-PD-1\u002FPD-L1 antibodies, anti-PD-L2 antibodies, anti-CD137 antibodies, CTLA-4 antibodies, or other drugs\u002Fantibodies targeting T-cell costimulatory or checkpoint pathways.\n\n  6\\. Severe, non-healing, or dehiscent wound, or active ulcer, or untreated fracture.\n\n  7\\. Any other serious physical or mental illness, or laboratory abnormalities that may increase the risk of study participation, interfere with study results, or render the subject unsuitable for the study judged by the investigator.",{"count":212,"type":21},332,[214],"PHASE3","This study is a randomized, controlled, open-label phase III clinical trial, aims to compare the efficacy and safety of Retlirafusp alfa injection plus CAPOX versus the investigator's choice of anti-PD-1 antibody plus CAPOX as first-line treatment in patients with advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC) with liver metastases",[217],"Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma","2026-06-24",{"date":220,"type":35},"2026-06-30",{"date":222,"type":21},"2026-06-26",{"date":65,"type":21},{"name":41,"class":42},{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":236,"conditions":237,"keywords":239,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":251},"100557709","phase-1-evm16-injection-as-a-single-and-combination-with-tislelizumab-in-solid-tumors-100557709","NCT06541639","EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors","A Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, and Initial Efficacy of EVM16 Injection as a Single and Combination With Tislelizumab in Subjects With Advanced or Recurrent Solid Tumors","Key Inclusion Criteria:\n\n* Recurrent or metastatic solid tumors that have been histologically or cytologically pathologically confirmed and are not amenable to radical treatment with surgery or local therapy.\n* Patients with advanced or recurrent solid tumors who have failed prior standard therapy.\n* Expected survival period \\>6 weeks at the time of informed consent.\n* Adequate organ function\n* Eastern Cooperative Oncology Group (ECOG) Physical Status Score 0 to 1.\n* Is willing to provide archival or fresh tumor tissue samples for EVM16 production.\n* Has adequate treatment washout period prior to first study dose.\n* Has at least one measurable lesion as assessed by the investigator according to RECIST version 1.1 criteria before enrollment.\n\nKey Exclusion Criteria:\n\n* Primary central nervous system (CNS) malignancies that are symptomatic, untreated, or in need of curative treatment, or subjects with CNS metastases.\n* Uncontrolled co-morbidities.\n* Cerebrovascular event (stroke, transient ischemic attack, etc.) within 4 months prior to the signing of inform consent form.\n* In screening period male QTcF interval \\>450 ms; Female QTcF interval \\>470 ms (calculated by the Fridericia formula).\n* Left ventricular ejection fraction (LVEF) \\\u003C 50% during the screening period.\n* Diagnosis of immunodeficiency, or history or syndrome of active as well as former autoimmune disease with risk of relapse, or a disease requiring systemic steroid hormone or immunosuppressive drug therapy.\n* Subjects with a history of positive human immunodeficiency virus (HIV) test or acquired immunodeficiency syndrome (AIDS).\n* Co-infection HBV and HCV.\n* Presence of any active infection requiring systemic therapy.\n* Patients who are still on any other investigational medications treatment at the time of screening.\n* Previous treatment with cell therapy, tumor vaccines, cytokines, or growth factors for cancer control.\n* Patients with prior intolerance to tislelizumab resulting in permanent termination of tislelizumab.\n* History or presence of significant lung disease.",{"count":233,"type":21},78,[235],"PHASE1","The goal of this clinical trial is to learn the side effects, safety and effect of a tumor vaccine (EVM16) alone or in combined with an anti-PD-1 antibody (tislelizumab) . This clinical trial will include solid tumor patients who failed standard treatment.\n\nThe main questions to answer are:\n\nSafety of EVM16. Suitable dose of EVM16. Effects of EVM16 combined with tislelizumab.",[238],"Advanced or Recurrent Solid Tumors",[240,241,242],"solid tumor","tumor vaccine","immune checkpoint inhibitor","2026-06-17",{"date":245,"type":35},"2026-06-22",{"date":247,"type":35},"2025-03-04",{"date":249,"type":21},"2028-12",{"name":41,"class":42},2,{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":75,"sex":16,"minAge":259,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":269,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":95},"100539629","3d-facial-scanning-for-evaluating-autologous-fat-grafting-in-craniofacial-deformities-100539629","NCT06306326","3D Facial Scanning for Evaluating Autologous Fat Grafting in Craniofacial Deformities","Application of Three-dimensional Facial Scanning Images in Evaluating the Therapeutic Efficacy of Autologous Fat Grafting in the Treatment of Craniofacial Deformities","Inclusion Criteria:\n\n* Facial soft tissue volume deficiency deformity caused by congenital\u002Facquired factors, meeting the indications for autologous fat grafting surgery.\n* Good physical health, without severe systemic diseases or infectious diseases.\n* Not pregnant and without plans for pregnancy.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Contraindications to general anesthesia.\n* Patient refusal to participate in this study.\n* Significant contour changes in non-filled facial areas during follow-up period leading to inability to register data.","3 Years","80 Years",{"count":262,"type":21},100,[24],"Treatment of craniofacial deformities is a significant topic in oral and maxillofacial surgery, and autologous fat grafting has become one of the main methods for treating facial concave deformities. However, the instability of its treatment effect has always been a bottleneck in this field, mainly due to the uncertain absorption rate of transplanted fat. This project aims to use advanced the 3dMD face system (3dMD) (3dMD Inc, Atlanta, Ga) technology to precisely measure the facial volume changes before and after autologous fat grafting to address this issue. By performing autologous fat grafting surgery on 100 patients with craniofacial deformities that meet the research criteria, 3dMD technology will be used for facial three-dimensional scanning preoperatively, immediately postoperatively, and at six months postoperatively to obtain facial volume data. Then, through precise data analysis, we will calculate the fat absorption rate and study the effects of individual factors on treatment outcomes through correlation regression analysis.",[266,267,268],"Adipocytes","Autografts","Imaging, Three-Dimensional \u002F Methods",[270,271],"Autologous Fat Grafting","3dMD","2026-06-05",{"date":274,"type":35},"2026-06-09",{"date":276,"type":35},"2024-04-27",{"date":278,"type":21},"2029-04-15",{"name":41,"class":42},{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":16,"minAge":288,"maxAge":18,"enrollmentInfo":289,"targetDuration":4,"studyType":22,"phases":291,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":95},"100638026","salt-sensitivity-evaluation-via-n-of-1-trials-sense-salt-100638026","NCT07614724","Salt Sensitivity Evaluation Via N-of-1 Trials (SENSE-Salt)","Determining the Presence of Salt Sensitivity in Individuals With Elevated Blood Pressure Through Dietary Salt Interventions: A Series of N-of-1 Trials","SENSE-Salt","Phase 1: Salt Sensitivity Screening\n\nInclusion:\n\n1. Signed informed consent for the salt sensitivity test.\n2. Systolic blood pressure between 110-159 mmHg and diastolic blood pressure between 70-99 mmHg.\n3. Not taking any antihypertensive medication, or have had a stable antihypertensive regimen for the past three months and agree not to adjust their medication during the study period.\n4. Able to comply with consuming the study-provided diet throughout the study period.\n\nExclusion:\n\n1. Special dietary requirements, such as allergies to common foods (e.g., eggs, seafood, peanuts), or conditions like asthma, irritable bowel syndrome, lactose intolerance, chronic kidney disease stage 4 or higher, history of gastrointestinal surgery, or special dietary needs due to other illnesses, surgery, or weight loss.\n2. Diagnosed with chronic diseases: any malignancy with a life expectancy of less than one year; chronic heart failure, severe depression or other mental disorders, long-term bedridden status, or mobility limitations.\n3. Experienced acute myocardial infarction or stroke within the past 6 months.\n4. Acute illnesses such as upper respiratory tract infection, fever, or severe diarrhea that have not yet resolved.\n5. Alcohol abuse.\n6. Pregnant or breastfeeding women, or women planning to become pregnant.\n7. Individuals who are deaf, mute, or have cognitive impairments that hinder communication.\n\nPhase 2: N-of-1 Trial\n\nInclusion:\n\n1. Classified as salt-sensitive or salt-resistant through the Phase 1 screening:\n2. Salt-Sensitive (SS) Group: Participants with a change in mean arterial pressure (ΔMAP) ≥ 5 mmHg and in the upper 1\u002F6 of the distribution of ΔMAP from the salt sensitivity test.\n3. Salt-Resistant (SR) Group: Participants with a change in mean arterial pressure (ΔMAP) \\\u003C 5 mmHg and in the lower 1\u002F6 of the distribution of ΔMAP from the salt sensitivity test.\n4. Signed informed consent for the n-of-1 trial.\n\nExclusion:\n\n1. Failed to complete the salt sensitivity test as required, or consumed less than 80% of the study-provided meals during the salt sensitivity test (i.e., fewer than 34 meals over 14 days).\n2. Experienced adverse events during the salt sensitivity test that, in the investigator's judgment, make it inappropriate to continue in the study.","20 Years",{"count":290,"type":21},72,[24],"Study Title: Determining the Presence of Salt Sensitivity in Individuals With Elevated Blood Pressure Through Dietary Salt Interventions: A Series of N-of-1 Trials\n\nObjective: To evaluate whether there are differences in blood pressure responses to dietary sodium intake between salt-sensitive and salt-resistant individuals, as identified through a salt sensitivity test. The study will use repeated dietary interventions with varying sodium content (high-sodium, low-sodium) to assess blood pressure responses in each individual, aiming to determine whether salt sensitivity is a present characteristic.\n\nStudy Design: This study will utilize an N-of-1 randomized controlled trial design. It consists of two phases:\n\nSalt Sensitivity Screening: A 2-week chronic salt-loading test will be used to identify salt-sensitive and salt-resistant individuals.\n\nN-of-1 Trial: The identified salt-sensitive and salt-resistant individuals will undergo a 6-week N-of-1 trial, consisting of three cycles, with each cycle including one week of low-sodium diet and one week of high-sodium diet. This design aims to assess individual blood pressure responses to changes in sodium intake.\n\nSample Size: A total of 72 participants will be recruited for the salt sensitivity screening, with an expected 24 participants proceeding to the N-of-1 trial.\n\nStudy Population: Healthy individuals aged 20-65 years, not on antihypertensive medication or with a stable regimen for at least 3 months, with systolic blood pressure between 110-159 mmHg and diastolic blood pressure between 70-99 mmHg, who are able to eat at the research center.\n\nPrimary Outcome: Reproducibility of salt sensitivity response classification. Secondary Outcomes: Changes in mean arterial pressure, systolic and diastolic blood pressure; exploratory outcomes such as sleep, mood, gut microbiome, metabolomics; safety outcomes including hypotension and hyponatremia.",[294,82],"Salt-Sensitivity of Blood Pressure",[296,297],"blood pressure","salt-sensitivity","2026-05-22",{"date":300,"type":35},"2026-05-29",{"date":302,"type":21},"2026-06-01",{"date":304,"type":21},"2026-11-30",{"name":41,"class":42},{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":16,"minAge":259,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":320,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":95},"100633877","fms-crossfit-training-program-fctp-to-improve-school-readiness-in-preschool-children-with-autism-spectrum-disorder-100633877","NCT07532395","FMS-CrossFit Training Program (FCTP) to Improve School Readiness in Preschool Children With Autism Spectrum Disorder","A Randomized Controlled Trial of the FMS-CrossFit Training Program (FCTP) to Improve School Readiness in Preschool Children With Autism Spectrum Disorder","Inclusion Criteria:\n\n1. age 3-6 years;\n2. confirmed ASD diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria or the Autism Diagnostic Observation Schedule-Second Edition (ADOS-2);\n3. written informed consent from parent\u002Fcaregiver.\n\nExclusion Criteria:\n\n1. participation in structured exercise programs within the preceding 6 months;\n2. comorbid severe neurological disorders (e.g., epilepsy, phenylketonuria, fragile X syndrome, tuberous sclerosis) or major psychiatric conditions (e.g., schizophrenia, bipolar disorder);\n3. visual, auditory or intellectual impairments that would interfere with participation;\n4. history of significant head trauma or brain injury;\n5. medical contraindications to physical activity ;\n6. other factors deemed unsuitable for program participation by the research team.","6 Years",{"count":315,"type":21},184,[24],"Autism spectrum disorder (ASD) is an increasing public health concern, with preschool children often exhibiting persistent deficits in school readiness. However, targeted and developmentally comprehensive interventions remain limited. This randomized controlled trial will evaluate a 12-week Fundamental Movement Skills-CrossFit Training Program (FCTP) in 184 children with ASD aged 3-6 years, compared with a Treatment As Usual (TAU) control group. The program integrates progressive FMS training with CrossFit-style circuit training to improve motor competence, social interaction, and self-regulation. Primary outcomes focus on school readiness assessed by the Strengths and Difficulties Questionnaire (SDQ), while secondary outcomes include motor development, executive function, social responsiveness, and biomarkers. Assessments will be conducted at baseline, mid-intervention (8 weeks), post-intervention (12 weeks), and follow-up (20 weeks).",[319],"Autism Spectrum Disorder",[319,321],"CrossFit",{"date":323,"type":35},"2026-05-27",{"date":325,"type":35},"2025-11-22",{"date":327,"type":21},"2027-04-24",{"name":41,"class":42},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":22,"phases":338,"briefSummary":339,"conditions":340,"keywords":345,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":95},"100560701","phase-2-immune-checkpoint-inhibitors-for-organ-preservation-in-non-metastatic-dmmrmsi-h-gastric-or-colon-cancers-100560701","NCT06580574","Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR\u002FMSI-H Gastric or Colon Cancers","PD-1\u002FPD-L1 Antibody With Selective Combination of Sintilimab, IBI310 and Lenvatinib Used for Organ Preservation in Non-metastatic Gastric or Colon Cancers With Mismatch Repair Deficiency or High Microsatellite Instability","Inclusion Criteria:\n\n* Subjects are able to comprehend the informed consent form, and voluntarily sign the informed consent form.\n* Subjects are ≥18 years old on the day of signing the informed consent form, with no gender restrictions.\n* Histologically confirmed gastric cancer or colon cancer, without distant metastasis based on CR or MR.\n* ECOG performance status of 0-2.\n* dMMR confirmed by immunohistochemistry or MSI-H confirmed by PCR and NGS. If MSI status and MMR status were not consistent, whether to enroll this patient should be determine by investigators. Patients with MMR heterogeneity in tumors could not be included.\n* Patients who are about to receive or are receiving 24 weeks of PD1\u002FPDL1 antibody monothearpy and have not had the first efficacy assessment.\n* Archived tumor tissue samples or freshly obtained tumor tissue samples are available.\n* Female subjects of childbearing potential or male subjects with partners of childbearing potential agree to use highly effective contraception from 7 days before the first dose until 120 days after the last dose. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose.\n* Subjects have the ability and willingness to comply with the study protocol's visits, treatment plan, laboratory tests, and other study-related procedures.\n* For patients who are about to receive combination of Sintilimab, IBI310 and Lenvatinib. subjects should have good organ function within the first 7 days of initial dosing: HGB ≥ 80g\u002FL, NEU ≥ 1.0\\*10\\^9\u002FL, PLT ≥ 75\\*10\\^9\u002FL, Cr≤1.5×ULN or CrCl≥50mL\u002Fmin（Cockcroft-Gault method), TBiL ≤ 1.5×ULN, ALT and AST ≤3 ×ULN; urine protein \\\u003C2+; if urine protein ≥ 2+, 24 hour urinary protein quantity \\\u003C2g; INR, APTT, PT ≤ 1.5 ×ULN\n\nExclusion Criteria:\n\n* Distant metastasis;\n* Previous treatment including CTLA4 blockade;\n* Subjects with interstitial lung disease or a history of non-infectious pneumonia requiring oral or intravenous corticosteroid treatment.\n* Subjects with active autoimmune diseases requiring systemic treatment before the start of the study or those considered at risk of recurrence or planned treatment for autoimmune diseases as judged by the investigator. Except for these conditions: a) skin diseases that do not require systemic treatment (e.g., vitiligo, alopecia, psoriasis, or eczema); b) hypothyroidism caused by autoimmune thyroiditis, requiring stable doses of hormone replacement therapy; c) type 1 diabetes requiring stable doses of insulin replacement therapy; d) childhood asthma fully resolved with no need for intervention in adulthood; e) the investigator judges that the disease will not relapse without external triggering factors.\n* Subjects with a history of other malignant tumors within 5 years, excluding cured skin squamous cell carcinoma, basal cell carcinoma, non-invasive bladder carcinoma, localized low-risk prostate cancer (defined as stage ≤T2a, Gleason score ≤6, and prostate-specific antigen (PSA) ≤10 ng\u002FmL (if measured) in patients who have undergone curative treatment and have no biochemical recurrence of prostate-specific antigen (PSA)), in situ cervical\u002Fbreast carcinoma, or Lynch syndrome.\n* Subjects with uncontrolled comorbidities, including but not limited to: a) active HBV or HCV infection; b) subjects who are HBsAg positive and\u002For HCV antibody positive during screening must undergo HBV DNA and\u002For HCV RNA testing. Only subjects with HBV DNA ≤500 IU\u002FmL (or ≤2000 copies\u002FmL) and\u002For HCV RNA negative can be enrolled; HBV DNA monitoring will be at the discretion of the investigator based on the subject's condition during the trial; c) known HIV infection or AIDS history; d) active tuberculosis; e) uncontrolled hypertension (resting blood pressure ≥160\u002F100 mmHg), symptomatic congestive heart failure (NYHA II-IV), unstable angina or myocardial infarction within 6 months, or the presence of QTc prolongation or the risk of arrhythmia (baseline QTc \\>470 msec \\\u003CFridericia method correction\\>, refractory hypokalemia, long QT syndrome, atrial fibrillation with resting heart rate \\>100 bpm, or severe valvular heart disease); f) active bleeding that cannot be controlled after medical treatment.\n* History of allogeneic bone marrow or organ transplantation.\n* Previous history of allergic reactions, hypersensitivity reactions, or intolerance to antibody drugs (e.g., severe allergic reactions, immune-mediated hepatotoxicity, immune-mediated thrombocytopenia, or anemia).\n* Pregnant and\u002For lactating females.\n* For patients who are about to receive combination of Sintilimab, IBI310 and Lenvatinib: a) Subjects with a history of gastrointestinal perforation or fistula within 6 months before the first dose. If the perforation or fistula has been treated with resection or repair, and the disease is judged to be recovered or improved by the investigator, then enrollment is allowed. b) Subjects who have undergone major surgery within 28 days before the first dose (e.g., major abdominal or thoracic surgery; excluding drainage, diagnostic puncture, or peripheral vascular access replacement). c) Subjects who require systemic corticosteroids (≥10 mg\u002Fday prednisone or equivalent) or immunosuppressive therapy for a continuous 7-day period within 14 days before the first dose. Inhaled or locally applied steroids and physiological replacement doses of steroids due to adrenal insufficiency are allowed. Short-term (≤7 days) corticosteroids for prophylaxis (e.g., contrast dye allergy) or treatment of non-autoimmune diseases (e.g., delayed hypersensitivity reaction caused by exposure to allergens) are allowed. d) Toxicity from previous antitumor treatments has not recovered to Grade ≤2 (NCI-CTCAE v5.0) or baseline, except for alopecia, skin pigmentation (allowed at any level), and immune-related adverse reactions requiring physiological replacement (e.g., hypothyroidism, hypopituitarism, type 1 diabetes).",{"count":337,"type":21},34,[54],"This study intends to explore the role of PD1\u002FPDL1 antibody with selective combination of Sintilimab, IBI310 and Lenvatinib in organ preservation in non-metastatic dMMR\u002FMSI-H gastric or colon cancers with mismatch repair deficiency or high microsatellite instability",[341,342,343,344],"Gastric Cancer","Colon Cancer","MSI-H","DMMR Cancer",[346,347,348],"Organ preservation","immunotherapy","anti-VEGF","2026-05-13",{"date":351,"type":35},"2026-05-15",{"date":353,"type":35},"2024-09-13",{"date":355,"type":21},"2029-06-01",{"name":41,"class":42},{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":16,"minAge":153,"maxAge":17,"enrollmentInfo":364,"targetDuration":4,"studyType":22,"phases":366,"briefSummary":367,"conditions":368,"keywords":370,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":251},"100617985","the-effectiveness-of-guided-written-exposure-therapy-for-complex-ptsd-in-adolescents-100617985","NCT07325734","The Effectiveness of Guided Written Exposure Therapy for Complex PTSD in Adolescents","The Effectiveness of Guided Written Exposure Therapy for Complex PTSD in Adolescents: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged between 10 and 18 years;\n2. Meet the diagnostic or subclinical criteria for Complex PTSD (C-PTSD), defined as missing at most one symptom from either the PTSD or DSO clusters;\n3. Possess sufficient literacy and language skills to complete writing-based tasks;\n4. Be able to understand the study procedures and complete the required assessments;\n5. Provide written informed consent, with consent also obtained from their legal guardians.\n\nExclusion Criteria:\n\n1. Presence of a severe psychiatric disorder or neurodevelopmental disorder, such as schizophrenia, bipolar I disorder, autism spectrum disorder, intellectual disability, or other severe psychiatric conditions that would interfere with study participation;\n2. Presence of a severe physical illness that would impair the ability to engage in the intervention;\n3. Assessed as being at high suicidal risk (e.g., current suicidal ideation with intent or plan, recent suicide attempt within the past 12 months, or severe self-harm behaviors);\n4. Ongoing exposure to traumatic events;\n5. Currently receiving other trauma-focused psychological treatments.",{"count":365,"type":21},130,[24],"This study aims to examine the effectiveness of group Guided Written Exposure Therapy for Complex Post-Traumatic Stress Disorder (GWE-C) among Chinese adolescents through a randomized controlled trial. A total of 120 participants will be recruited, with 60 randomized to the GWE-C group and 60 randomized to the supportive therapy (ST) group. The GWE-C intervention will consist of 7 to 10 group sessions. The primary outcome, assessed by the International Trauma Questionnaire (ITQ), will be measured at baseline, post-treatment, 1-month follow-up, and 3-month follow-up.",[369],"CPTSD, Compelx Post-traumatic Stress Disorder",[371,372,373],"adolescents","randomized controlled trial","Complex PTSD","2026-05-12",{"date":376,"type":35},"2026-05-14",{"date":378,"type":35},"2025-10-10",{"date":380,"type":21},"2026-12-25",{"name":41,"class":42},{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":75,"sex":16,"minAge":153,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":22,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":95},"100640494","ai-gf-gnw-on-prolonged-grief-reactions-100640494","NCT07589088","AI-GF-GNW on Prolonged Grief Reactions","AI-Assisted Grief-Focused Guided Narrative Writing for Subclinical Prolonged Grief Disorder in Bereaved Chinese Adolescents: A Three-Arm Parallel Randomized Controlled Trial.","Inclusion Criteria:\n\n* Junior and senior high school students currently studying in Chinese Mainland, aged 10-19;\n* Between 6 and 60 months prior to the experimental period, experienced the death of a significant family member or close friend or close friend;\n* The total symptom score of PG-13-R is between 20-29 points;\n* Ability to write and understand written guidelines, to use the mobile phone to interact with AI;\n* Consent to participate in the study.\n\nExclusion Criteria:\n\n* Diagnosed or previously diagnosed with mental illness\n* The bereavement time does not meet the time window\n* PG-13-R score is not within the range\n* At present, there is suicidal ideation or recent severe self harm behavior (Reynolds' Suicidal Ideation Questionnaire, SIQ-JR-4\\>0), and a crisis intervention hotline is provided when necessary.\n* Has received other grief counseling or is currently taking psychiatric medication within the past month","19 Years",{"count":391,"type":21},126,[24],"Prolonged Grief Disorder (PGD) is a severe, disabling condition characterized by intense yearning and difficulty accepting the reality of loss, which significantly impairs the academic and psychosocial functioning of bereaved adolescents. While Grief-Focused Cognitive Behavioral Therapy (GF-CBT) is effective, its high cost and resource-intensive nature limit its accessibility for adolescents in mainland China. Grief-Focused Guided Narrative Writing (GF-GNW) offers a scalable, low-cost alternative that facilitates memory integration.\n\nFurthermore, integrating Artificial Intelligence (AI) to provide personalized, structured feedback has the potential to simulate therapist functions and enhance intervention efficacy. However, the specific efficacy of AI-assisted feedback in this context remains empirically unvalidated.\n\nThis parallel randomized controlled trial aims to examine the effectiveness of AI-assisted GF-GNW (AI-GF-GNW) in treating Chinese adolescents (aged 10-19) with subclinical PGD, compared to a no-feedback NF-GF-GNW group and a free writing group. Primary outcomes include PGD symptom severity, while secondary outcomes assess depression, anxiety, and daily functioning. We hypothesize that both active intervention arms will significantly alleviate PGD and related symptoms compared to the free writing group, and that the AI-GF-GNW group will demonstrate a significantly greater reduction in symptoms and functional impairment than the NF-GF-GNW group.",[395,396,27,111,397],"Artificial Intelligence (AI)","Prolonged Grief Symptoms","Disabilities","2026-05-09",{"date":351,"type":35},{"date":401,"type":21},"2026-05-25",{"date":403,"type":21},"2027-05",{"name":41,"class":42},{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":260,"enrollmentInfo":412,"targetDuration":4,"studyType":22,"phases":414,"briefSummary":415,"conditions":416,"keywords":418,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":251},"100628791","haic-plus-systemic-therapy-as-de-escalation-therapy-strategy-for-biliary-tract-cancer-100628791","NCT07466238","HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer","HAIC Combined With Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer: A Conceptual Study","Inclusion Criteria:\n\n* Age: 18-80 years, both genders.\n* Diagnosis of biliary tract cancer (including intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, and gallbladder cancer) and confirmed by histopathological or cytopathological examination.\n* Without distant metastasis or limited distant metastasis\n* Treatment-naive.\n* ECOG PS score \\\u003C 2.\n* Child-Pugh score: Class A or B (≤7).\n* Normal major organ function, meeting the following standards:(1) Blood routine examination:A. Hb≥90 g\u002FL;B. ANC≥1.5×10\\^9\u002FL;C. PLT≥75×10\\^9\u002FL;(2) Biochemical examination:A. ALB ≥30g\u002FL;B. ALT and AST\\\u003C5×ULN;C. TBiL ≤5×ULN;D. Creatinine ≤1.5×ULN;(3) Coagulation function:A. International normalized ratio (INR) ≤1.5×ULN;B. Activated partial thromboplastin time (APTT) ≤1.5×ULN.\n\nExclusion Criteria:\n\n* Coexistent or synchronous malignancies.\n* Distal cholangiocarcinoma.\n* Allergic to contrast agents or oxaliplatin.\n* Pregnant or lactating women.\n* Multiple extrahepatic metastases or combined malignant pleural and peritoneal effusions.\n* History of organ transplantation.\n* With infections requiring anti-infection treatment.\n* Severe and irreparable coagulation dysfunction.",{"count":413,"type":21},40,[24],"Biliary tract cancer (BTC), including cholangiocarcinoma and gallbladder cancer (GBC), is a group of malignancies with highly heterogeneous, highly aggressiveness, and poor prognosis. Surgery is recognized as the only curative treatment for BTC, however, only about 20% BTC patients are eligible for curative resection since most patients with BTC are diagnosed at an advanced stage. The median overall survival (OS) in patients with unresectable BTC is typically less than 6 months. For patients with unresectable BTC, gemcitabine plus cisplatin (GemCis) had been recommended as the standard first-line treatment for many years. However, the objective response rate (ORR) of this regimen is only 26.1%, and the survival benefit remains limited, with a median OS of less than one year.\n\nIn recent years, two phase III trials (TOPAZ-1 and KEYNOTE-966) have demonstrated that combining immune checkpoint inhibitors (durvalumab or pembrolizumab) with the GemCis regimen could further prolong survival in patients with BTC, achieving a median OS of 12.9 months and 12.7 months, respectively. Based on this evidence, many guidelines worldwide had recommended GemCis plus durvalumab or pembrolizumab as the preferred standard first-line treatment for patients with unresectable BTC. However, survival benefits from this combination therapy remain relatively limited, and tumor response is suboptimal, with an ORR of only 26.7%-29%.\n\nHepatic arterial infusion chemotherapy (HAIC) enables continuous infusion of chemotherapeutic agents via the hepatic artery, significantly increasing local drug concentration at the tumor site, maximizing antitumor efficacy, and achieving a higher ORR (50%-60%) with substantial reduction in tumor burden. In recent years, HAIC has been increasingly used in the treatment of unresectable BTC, with its efficacy supported by many clinical studies.\n\nFirstly, HAIC provides survival benefits comparable to surgery in patients with multifocal intrahepatic cholangiocarcinoma (iCCA), and significantly outperforms systemic therapy. In 2022, a retrospective study enrolled 141 patients who received HAIC and 178 patients who underwent surgical resection from 12 centers. The results showed the median OS was 20.3 months in the HAIC group and 18.9 months in the resection group (P = 0.32), indicating comparable survival outcomes between HAIC and surgery. Given the risks of post-hepatectomy complications, HAIC may serve as an effective alternative treatment strategy for multifocal iCCA. Furthermore, for locally advanced unresectable iCCA, the results in a study in 2024 comparing HAIC with GemCis regimen chemotherapy revealed that although patients in the HAIC group had a higher tumor burden (proportion of multifocal disease: 73.4% vs. 55.3%, P = 0.023), the median OS in HAIC group remained significantly superior to that in the GemCis group (27.7 months vs. 11.8 months, P \\\u003C 0.001).\n\nSecondly, HAIC has also been demonstrated to be effective in treating perihilar cholangiocarcinoma (pCCA). In 2017, a single-arm, prospective phase II trial conducted in our center showed HAIC with oxaliplatin and fluorouracil yielded an ORR of 67.6%, a median progression-free survival (PFS) of 12.2 months, and a median OS of 20.5 months in treating perihilar cholangiocarcinoma (pCCA).\n\nFurthermore, HAIC also has clinical potential in treating advanced GBC. In 2021, a retrospectively study in our center enrolled 26 patients with advanced GBC who received HAIC with oxaliplatin and fluorouracil, of whom 23.1% had failed prior systemic therapy and 34.6% had contraindications to systemic treatment. The results showed that HAIC achieved a median PFS of 10 months and a median OS of 13.5 months, with an ORR of 69.2% and a disease control rate (DCR) of 92.3%.\n\nIn recent years, many studies have demonstrated that HAIC combined with systemic therapy could yield significant survival benefits in patients with unresectable BTC. A phase II clinical trial in 2022 evaluated the efficacy of HAIC with floxuridine plus systemic gemcitabine and oxaliplatin (GEMOX) in unresectable iCCA. The results showed that the combination therapy achieved a median PFS of 11.8 months and a median OS of 25 months, with a 6-month DCR of 84%, and 58% of patients achieved partial response (PR). Additionally, the association of benefit of combining HAIC with systemic chemotherapy and stage of BTC has been reported, and that patients with locally advanced cholangiocarcinoma may not derive such benefit from this combination. In 2025, a phase II clinical trial conducted in our center evaluated the efficacy and safety of HAIC (bevacizumab, oxaliplatin, and fluorouracil) combined with toripalimab as a first-line treatment for unresectable BTC. The results showed a median PFS of 13.2 months and a median OS of 19 months, with an ORR as high as 84.38%. Some patients achieved successful conversion resection following this combination therapy, and postoperative pathology confirmed pathological complete res",[417],"Biliary Tract Cancer (BTC)",[419,420,421],"biliary tract cancer","hepatic arterial infusion chemotherapy","systemic therapy","2026-05-05",{"date":424,"type":35},"2026-05-08",{"date":426,"type":35},"2026-03-31",{"date":428,"type":21},"2029-03-31",{"name":41,"class":42},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":436,"targetDuration":4,"studyType":22,"phases":438,"briefSummary":439,"conditions":440,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":449,"locationsCount":95},"100614506","weekly-dynamics-of-psychopathological-and-symptom-networks-during-mindfulness-based-interventions-for-emotional-distress-100614506","NCT07280481","Weekly Dynamics of Psychopathological and Symptom Networks During Mindfulness-Based Interventions for Emotional Distress","Inclusion Criteria:\n\n* experiencing emotional distress such as depression or anxiety (Kessler-10 score \\> 21)\n\nExclusion Criteria:\n\n* prior experience with mindfulness meditation\n* current self-harm or suicidal risk\n* bipolar disorder or schizophrenia\n* history of substance abuse\n* severe personal trauma history",{"count":437,"type":21},500,[24],"The goal of this clinical study is to learn how Mindfulness Intervention for Emotional Distress (MIED) helps people with emotional distress and how their symptoms and psychological patterns change over time.\n\nThe main questions it aims to answer are:\n\n* How do the relationships between emotions, thoughts, and behaviors change week by week during mindfulness training?\n* Which psychological skills, such as distress tolerance or cognitive flexibility, improve first and lead to later emotional relief? Two groups will be compared - one that takes part in an online mindfulness intervention and one that waits to join - to see how the intervention changes emotional and psychological networks over time.\n\nParticipants will:\n\n* Complete a 7-week online self-guided Mindfulness Intervention for Emotional Distress（iMIED） designed for people experiencing high emotional distress.\n* Fill out short weekly questionnaires about their emotions, thoughts, and behaviors before, during, and after the course (9 times in total).\n* Receive access to the mindfulness program after the study if they are in the wait-list group.\n\nThis study includes about 500 adults aged 18 and older who feel anxious, depressed, or emotionally distressed but have no major psychiatric disorders. By tracking weekly changes, the research aims to identify how mindfulness intervention leads to emotional improvement and which skills play the most important roles in that process.",[441,442],"Depression, Anxiety","Emotional Disorders","2026-04-24",{"date":445,"type":35},"2026-04-27",{"date":447,"type":35},"2025-11-16",{"date":298,"type":21},{"name":41,"class":42},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":75,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":460,"phases":4,"briefSummary":461,"conditions":462,"keywords":463,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":95},"100584728","ctdna-mrd-monitoring-after-resection-in-gastric-cancer-100584728","NCT06893133","ctDNA-MRD Monitoring After Resection in Gastric Cancer","Personalized ctDNA-MRD in Recurrence Monitoring for Gastric Cancer Patients Undergoing Perioperative Treatment Combined With Curative Surgical Resection","MRD-GC","Inclusion Criteria:\n\n1. Patients have received neoadjuvant therapy and radical resection (R0).\n2. Pathologically confirmed ypTNM stage II-III gastric or gastroesophageal junction adenocarcinoma.\n3. Patients must be able to provide sufficient fresh tissue\u002Fbiopsies or minimum 5-10 FFPE sections for NGS-WES analysis.\n4. Patients must be able to follow the study visit schedule and be willing to cooperate with the study by providing blood samples at the indicated time point.\n\nExclusion Criteria:\n\n1. Patients who could not receive enhanced CT, gastroscopy and other routine review after surgery.\n2. Patients who could not perform WES or ctDNA-MRD detection for various reasons after surgery.\n3. Other cases considered unsuitable for inclusion by researchers.",{"count":459,"type":21},110,"OBSERVATIONAL","Numerous studies have demonstrated that circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection has significant clinical value in postoperative recurrence monitoring, adjuvant treatment decision-making, and early intervention. Our previous retrospective study, using fixed ctDNA-MRD, confirmed that postoperative ctDNA-MRD can predict recurrence risk. Therefore, we plan to conduct a further prospective, multicenter, observational study, utilizing a combination of personalized ctDNA-MRD and fixed MRD panels, to dynamically monitor gastric cancer patients who have received neoadjuvant therapy followed by curative resection. The study will systematically analyze the correlation between ctDNA-MRD status and tumor recurrence and metastasis, assess its sensitivity and specificity in recurrence prediction, and compare its early warning advantage over traditional imaging techniques in predicting recurrence.",[341],[464,465,341],"ctDNA","MRD","2026-04-19",{"date":468,"type":35},"2026-04-21",{"date":470,"type":35},"2025-04-08",{"date":472,"type":21},"2027-04-30",{"name":41,"class":42},{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":481,"targetDuration":4,"studyType":22,"phases":483,"briefSummary":484,"conditions":485,"keywords":491,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":95},"100628166","the-step-mied-trial-digital-stepped-care-for-emotional-disorders-100628166","NCT07458100","The STEP-MIED Trial: Digital Stepped-Care for Emotional Disorders","Effectiveness and Cost-effectiveness of a Digital Stepped-care Mindfulness Intervention for Recovery From Emotional Disorders: a Multicentre Pragmatic Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age: 18-65 years.\n2. Diagnosed with an emotional disorder by a outpatient psychiatrist, including depressive disorders, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, agoraphobia, social anxiety disorder), obsessive-compulsive disorder, post-traumatic stress disorder, and eating disorders (e.g., anorexia nervosa, bulimia nervosa).\n3. Symptom severity meeting the threshold: PHQ-9 score ≥10 or GAD-7 score ≥8.\n\nExclusion Criteria:\n\n1. Current diagnosis of psychotic disorders or bipolar disorder.\n2. Current organic mental disorders, pervasive developmental disorders, severe cognitive impairment, or substance use disorders.\n3. Current suicide risk (PHQ-9 item 9 score \\>2).\n4. Antisocial personality disorder.\n5. Severe medical illnesses that may affect intervention participation or require recent hospitalization.\n6. Previous participation in a systematic 8-week mindfulness course.\n7. Inability to access the internet.",{"count":482,"type":21},464,[24],"The goal of this clinical trial is to evaluate the effectiveness and cost-effectiveness of a digital mindfulness-based intervention in adults (aged 18-65) diagnosed with emotional disorders like depression or anxiety. The main questions it aims to answer are:\n\n* Does adding a digital mindfulness intervention to usual care help people recover from emotional disorders faster and more sustainably over two years?\n* Is this combined approach more cost-effective than usual care alone? Researchers will compare the group receiving the digital mindfulness intervention plus their usual treatment to the group receiving only their usual treatment to see if the intervention leads to better long-term recovery and represents good value for money.\n\nParticipants in the intervention group will:\n\n* Attend eight weekly 2-hour online group mindfulness sessions.\n* Use a WeChat mini-program for 49 days of guided mindfulness exercises and daily tasks.\n* Patients who have not achieved reliable recovery after group retraining voluntarily participate in individual UP\\&MIED counseling.\n* Complete regular questionnaires and interviews over two years to track their progress.\n\nAll participants will continue to receive their usual medical care from their doctors throughout the study.",[442,486,487,488,489,490],"Depressive Disorder","Anxiety Disorders","Obsessive-Compulsive Disorder","Post-Traumatic Stress Disorder, PTSD","Eating Disorders",[492,493,494,372,495,442],"Cost-effectiveness","Mindfulness","Recovery","stepped-care","2026-04-18",{"date":468,"type":35},{"date":499,"type":35},"2026-03-23",{"date":501,"type":21},"2028-05",{"name":41,"class":42},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":16,"minAge":511,"maxAge":512,"enrollmentInfo":513,"targetDuration":4,"studyType":22,"phases":515,"briefSummary":516,"conditions":517,"keywords":519,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":95},"100632856","fangshan-active-nutrition-initiative-100632856","NCT07519122","Fangshan Active Nutrition Initiative","Research on Weight Management of School-age Children in Fangshan District Based on a Digital Intelligence Platform","FAN","Inclusion Criteria:\n\n* Schools will be selected based on the consent of primary leadership, demonstrated cooperation, and availability of necessary personnel (e.g., school health professionals).\n* Classes will be limited to grades 2 and 3, with teachers showing strong willingness to collaborate.\n* Both parental informed consent and child assent are required for participation.\n\nExclusion Criteria:\n\n* Schools will be excluded if they cater to special populations (e.g., schools for children with disabilities), are involved in other obesity-related interventions within the specified timeframe, or plan to close or relocate within two years.\n* Children will be excluded if they have histories of major organ diseases (e.g., cardiac, pulmonary, hepatic, or renal conditions), special diets (e.g., vegetarian), pathological eating disorders, physical limitations affecting activity, or obesity due to endocrine disorders or medication side effects.","8 Years","9 Years",{"count":514,"type":21},1400,[24],"The goal of this study is to evaluate the effectiveness of a school-based weight management intervention delivered through a digital platform (WeChat) in preventing excessive weight gain and improving health behaviors in school-aged children in Fangshan District, Beijing. The main questions it aims to answer are:\n\nDoes the intervention group show a significantly lower mean increase in BMI, body fat percentage, and waist circumference compared to the control group? Does the intervention group show a significantly lower obesity rate and new obesity incidence compared to the control group? Does the intervention group show significant improvements in healthy eating, sedentary behavior, sleep, physical activity, and physical fitness test scores compared to the control group? Researchers will compare children in intervention schools (who receive the multi-level intervention targeting students, families, and schools, supported by a digital platform for behavior monitoring and feedback) to children in control schools (who do not receive the intervention during the study period).\n\nParticipants in the intervention group will: (1) attend 10 student health education sessions; (2) have their physical activity at school increased to 60 minutes\u002Fday of moderate-to-vigorous activity; (3) have parents attend health education lectures and use a WeChat platform to receive health information, log child health data, and receive automated feedback; (4) have their height, weight, waist circumference, and body composition measured monthly by school health staff; and (5) be followed with assessments at 6, 12, and 24 months.",[518],"Childhood Weight Management",[520,521,522,523,524],"School-aged","Intervention","Overweight","Obesity","Children","2026-04-12",{"date":527,"type":35},"2026-04-15",{"date":529,"type":21},"2026-04-20",{"date":531,"type":21},"2029-04-30",{"name":41,"class":42},{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":4,"eligibilityCriteria":539,"healthyVolunteers":12,"sex":540,"minAge":17,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":22,"phases":543,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":553,"locationsCount":251},"100631357","digital-health-intervention-for-early-identification-and-prevention-of-gestational-diabetes-mellitus-100631357","NCT07499622","Digital Health Intervention for Early Identification and Prevention of Gestational Diabetes Mellitus","A Multicenter Randomized Controlled Trial of a Digital Health Intervention for Risk Identification, Intelligent Early Warning, and Prevention of Gestational Diabetes Mellitus Based on Multi-Source Data Integration","Inclusion Criteria:\n\n* Pregnant women in early pregnancy (within 13 weeks and 6 days of gestation)\n* Planned delivery at a participating study hospital\n* Age 18 years or older\n* Singleton pregnancy\n* Identified as high risk for gestational diabetes mellitus by the study risk assessment model\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* • Pre-pregnancy diabetes mellitus or overt diabetes diagnosed at the first antenatal visit (fasting blood glucose greater than or equal to 7.0 mmol\u002FL)\n\n  * Pre-existing hypertension, autoimmune disease, major infection, or severe liver or kidney disease\n  * Use of medications that affect glucose metabolism, such as corticosteroids or metformin\n  * Severe psychiatric disorders\n  * Inability or unwillingness to comply with study procedures","FEMALE",{"count":542,"type":21},1200,[24],"This study aims to develop and evaluate an early risk identification and digital health intervention strategy for gestational diabetes mellitus (GDM) among pregnant women in China. Gestational diabetes mellitus is a common pregnancy complication associated with adverse maternal and neonatal outcomes, including excessive gestational weight gain, macrosomia, cesarean delivery, and increased long-term risk of metabolic disorders in both mothers and offspring.\n\nThe study includes two components. First, retrospective multi-source clinical data from maternal health records will be used to develop and validate a risk prediction model for early identification of pregnant women at high risk of GDM. Second, pregnant women identified as high risk in early pregnancy will be enrolled in a multicenter randomized controlled trial and assigned to either a digital health intervention group or a usual care group. The intervention includes online health education, individualized lifestyle guidance, behavioral self-management tools, and interactive consultation through a digital platform. The primary outcome is the incidence of GDM diagnosed during pregnancy. Secondary outcomes include gestational weight gain, cesarean delivery, macrosomia, and other maternal and neonatal outcomes.\n\nThis study is expected to provide evidence for improving early risk assessment, intelligent warning, and prevention strategies for GDM in the context of maternal health management in China.",[546],"Gestational Diabetes Mellitus (GDM)","2026-03-24",{"date":549,"type":35},"2026-03-30",{"date":551,"type":21},"2026-06",{"date":249,"type":21},{"name":41,"class":42},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":561,"enrollmentInfo":562,"targetDuration":4,"studyType":22,"phases":564,"briefSummary":565,"conditions":566,"keywords":568,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":95},"100630363","phase-1-the-phase-i-study-of-sig001-antibody-on-cancer-therapy-100630363","NCT07486700","The Phase I Study of SIG001 Antibody on Cancer Therapy.","An Open-label, Phase I, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of SIG001 in Subjects With Advanced Solid Tumors.","Inclusion Criteria:\n\n* Subjects must meet all of the following criteria to be eligible for this clinical study:\n\n  1. The subject must fully understand the requirements of this study and voluntarily sign a written informed consent form. They must also be able to comply with the study's medication regimen as well as all related procedures and assessments;\n  2. Age must be \\>=18 and \\\u003C=75 years old, with no gender restriction;\n  3. Subjects must have locally advanced, recurrent, or metastatic malignant tumors that have failed standard treatment or are not tolerant to it, and for which there is no effective standard treatment option. Histological or cytological confirmation is required;\n  4. According to RECIST v1.1, the subject must have at least 1 measurable target lesion. At baseline, the lesion must be accurately measurable by computed tomography (CT) or magnetic resonance imaging (MRI) - preferably with intravenous contrast agent. The long diameter of non-lymph node lesions must be ≥10 mm, and the short axis of lymph node lesions must be \\>=15 mm. The lesion must be suitable for repeated and accurate measurements. If a lesion in a previously irradiated area shows clear progression, it can also be considered a measurable target lesion;\n  5. The expected survival time must be \\>=12 weeks;\n  6. The Eastern Cooperative Oncology Group performance status score must be 0 or 1;\n  7. Subjects must have adequate function of vital organs at the time of screening. This requires that no blood transfusions, hematopoietic stimulants, or human albumin preparations have been used within 14 days prior to screening. The specific criteria are as follows:\n\n  \u003C!-- -->\n\n  1. Blood tests: Absolute neutrophil count \\>=1.5 × 10\\^9\u002FL; Platelet count \\>=75 × 10\\^9\u002FL; Hemoglobin \\>=90 g\u002FL;\n  2. Liver function: Serum TBIL \\\u003C=1.5 × ULN. For patients with liver metastases or Gilbert's syndrome, TBIL \\\u003C=3 × ULN. For subjects without liver metastases, ALT and AST \\\u003C=2.5 × ULN; for those with liver metastases, ALT and AST \\\u003C=5 × ULN;\n  3. Coagulation function: Activated partial thromboplastin time and International normalized ratio \\\u003C=1.5 × ULN (for subjects on anticoagulant therapy, these values must be within the therapeutic range).\n  4. Renal function: Creatinine clearance rate \\>=60 mL\u002Fmin, calculated using the Cockcroft-Gault formula;\n  5. Cardiac function: Echocardiography shows left ventricular ejection fraction greater than 50%; 8. Female subjects of childbearing age must have a negative pregnancy test within 7 days before receiving the study drug for the first time. Eligible male and female subjects must agree to use reliable contraceptive methods (hormonal, barrier methods, or abstinence) during the study and for at least 6 months after the last dose of the drug. Eligible subjects are defined as being sexually mature and biologically capable of reproducing.\n\nExclusion Criteria:\n\n* Subjects will be excluded if they meet any of the following criteria:\n\n  1. SIG001 is administered during the washout period following previous antineoplastic therapy (4 weeks or 5 half-lives after the last dose, whichever is shorter);\n  2. Received radiotherapy within 28 days prior to the first dose of SIG001;\n  3. Acute toxicity resulting from previous antineoplastic therapy had not resolved to NCICTCAE 5.0 version grade ≤1 or to the baseline level specified in the inclusion criteria 4 weeks before the first dose of SIG001 (excluding hair loss or fatigue);\n  4. Had a history of other malignant tumors within 5 years prior to the first dose (except for non-melanoma skin basal cell carcinoma or squamous cell carcinoma that has been cured with no evidence of recurrence, breast\u002Fcervical carcinoma in situ, superficial bladder carcinoma, and other in situ cancers);\n  5. Subjects with any of the following cardiovascular diseases:\n\n  \u003C!-- -->\n\n  1. Symptomatic heart failure (New York Heart Association functional class \\>=2, see Appendix 4);\n  2. Uncontrolled hypertension despite standard treatment (systolic blood pressure \\>=160 mmHg or diastolic blood pressure \\>=100 mmHg);\n  3. Resting mean corrected QT interval \\> 470 ms on a 12-lead electrocardiogram (QTc, using Fridericia's correction formula) on three repeated measurements. Various clinically significant arrhythmias, conduction abnormalities, and resting ECG abnormalities, such as complete left bundle branch block, third-degree block, second-degree block, and PR interval \\> 250 ms. Factors that may increase the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, a family history of long QT syndrome or sudden death before age 40, and use of medications known to prolong QTc;\n  4. Acute coronary syndrome\u002Facute myocardial infarction, unstable angina pectoris, percutaneous coronary intervention or coronary artery bypass grafting within 6 months prior to screening;\n  5. Any cause of cardiomyopathy;\n  6. Clinically significant valvular heart disease;\n  7. History of atrial or ventricular arrhythmias that require treatment; subjects with atrial fibrillation and well-controlled ventricular rate may be enrolled;\n  8. Transient ischemic attack or stroke within 6 months prior to screening; 6. Subjects with infectious diseases, including;\n\n  \u003C!-- -->\n\n  1. Acute or chronic active hepatitis B, defined as positive for hepatitis B surface antigen (HbsAg) and\u002For hepatitis B core antibody (HbcAb) with HBV DNA \\>=100 IU\u002FmL;\n  2. Acute or chronic active hepatitis C, i.e., positive for HCV antibodies with HCV-RNA levels above the upper limit of the central reference range;\n  3. HIV-infected individuals (positive for HIV 1\u002F2 antibodies);\n  4. Active syphilis or active pulmonary tuberculosis; 7. Subjects with primary central nervous system tumors, meningeal metastases, spinal cord compression, or brainstem metastases; those with untreated brain metastases or symptomatic\u002Fstable conditions can be enrolled after at least 4 weeks of stable treatment; 8. Uncontrolled comorbidities, such as:\n\n  \u003C!-- -->\n\n  1. Severe infections within 4 weeks prior to study initiation, including hospitalization due to infection, bacteremia, or severe pneumonia; subjects with uncontrolled active infections during screening can be enrolled if they receive prophylactic antibiotics (e.g., for urinary tract infections or chronic obstructive pulmonary disease);\n  2. History of interstitial lung disease, unresolved radiation pneumonitis, acute episodes or progressive worsening of pulmonary symptoms at baseline, or factors that increase the risk of interstitial lung disease and pose a safety risk to the subject as assessed by the investigator;\n  3. Severe malnutrition requiring intravenous nutrition; subjects whose malnutrition has been corrected and stabilized for more than 4 weeks prior to the first dose can be enrolled;\n  4. Tumors invading vital organs or blood vessels, which may significantly increase treatment risk or affect efficacy assessment; subjects with a risk of esophagotracheal fistula or esophagothoracic fistula, or those within 4 weeks of esophageal or tracheal stent placement (subjects with stable conditions for more than 4 weeks can be enrolled);\n  5. History of gastrointestinal perforation and\u002For fistula within 6 months prior to screening;\n  6. Presence of uncontrolled effusions requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Subjects without the need for drainage or with no significant increase in effusion volume after 3 days of drainage cessation can be enrolled).\n\n  9\\. Subjects who are expected to receive other antineoplastic treatments during the study period (palliative radiotherapy is allowed); 10. Subjects who have participated in clinical studies within 4 weeks prior to the first dose or plan to participate in other clinical studies during the study period; 11. Subjects who have received live vaccines within 4 weeks prior to the first dose; 12. Allergy to SIG001 or its components; 13. Pregnant women, lactating women, or women who plan to become pregnant during the study period; 14. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 15. Subjects who have received systemic immunosuppressive therapy for autoimmune diseases within 2 years prior to dosing are excluded, except in the following cases:\n  1. Inhaled, topical, or intramuscular steroid use;\n  2. Systemic corticosteroids (dose not exceeding 10 mg\u002Fday of prednisone or equivalent);\n  3. Steroids used as premedication for hypersensitivity reactions (e.g., premedication for CT scans).\n\n  16\\. Subjects with a history of mental disorders and those taking medication for treatment; 17. Subjects with a history of drug abuse or substance use; 18. Subjects who, in the judgment of the investigator, have other factors that may affect the study results or interfere with their participation in the entire study, including past or current health conditions, treatment or laboratory test abnormalities, and those who are unwilling to comply with the study procedures and requirements.","75 Years",{"count":563,"type":21},66,[235],"The goal of this clinical trial is to learn the safty characteristics of SIG001 Mab in cancer patients; It will also determine the Recommended Phase II dose of SIG001 Mab on cancer treatment, and pharmacological characteristics of SIG001. The main questions it aims to answer are:\n\nWhat is the safety and tolerability of SIG001 in patients with advanced solid tumors ? What is the Recommended Phase II dose of SIG001? What is the PK\u002FPD characteristics of SIG001 in cancer patients? What is the antitumor activity of SIG001 in cancer patients? What is the immunogenicity of SIG001 in cancer patients? What is the relationship between the exposure\u002Fdose of SIG001 and its safety as well as clinical efficacy? What is the expression levels of potential biomarkers (such as SIG), if applicable, and analyze their correlation with drug exposure, efficacy, and safety? What is event-related endpoints such as the Duration of Response and Progression-Free Survival in patients treated with SIG001?\n\nThis will be a single-armed study.\n\nParticipants will:\n\nIntravenously Inject SIG001 every two weeks, for 4 weeks Visit the clinic on the 14th day, 30th day, and 90th day afer the last injection. Then visit the clinic for every 12 weeks.",[567],"Neoplams",[569,570,571],"neoplams","tumor IgG","sialylated IgG","2026-03-17",{"date":37,"type":35},{"date":575,"type":21},"2026-03",{"date":577,"type":21},"2028-07",{"name":41,"class":42},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":4,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":22,"phases":588,"briefSummary":589,"conditions":590,"keywords":592,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":4},"100627853","phase-1-intraperitoneal-px-in-combination-with-nab-paclitaxel-in-patients-with-peritoneal-metastatic-mucinous-adenocarcinoma-100627853","NCT07454031","Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma","An Investigator-Initiated Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma","Inclusion Criteria:\n\n* Age ≥ 18 years, regardless of sex;\n* Histologically confirmed peritoneal metastatic mucinous adenocarcinoma;\n* Considered suitable for intraperitoneal therapy based on investigator assessment;\n* ECOG performance status 0-2;\n* Adequate organ function confirmed by laboratory tests within 7 days prior to enrollment:\n* Hematology: ANC ≥ 1.5 × 10⁹\u002FL; PLT ≥ 100 × 10⁹\u002FL; Hb ≥ 85 g\u002FL; Liver function: TBIL ≤ 1.5 × ULN (≤ 3 × ULN for Gilbert's syndrome);AST\u002FALT ≤ 3 × ULN (≤ 5 × ULN in patients with liver metastases); Renal function: creatinine clearance ≥ 60 mL\u002Fmin (Cockcroft-Gault) or serum creatinine ≤ 1.5 × ULN; Coagulation: PT, INR, and APTT ≤ 1.5 × ULN;\n* Life expectancy ≥ 3 months;\n* Ability to understand and willingness to sign written informed consent.\n\nExclusion Criteria:\n\n* Planned concomitant systemic anti-tumor therapy during intraperitoneal treatment;\n* Massive ascites not expected to be adequately drained prior to dosing;\n* Chemotherapy or radiotherapy within 4 weeks prior to enrollment (≥ 6 weeks for nitrosoureas or mitomycin C);\n* Pregnancy or lactation, or unwillingness to use effective contraception;\n* Severe abdominal infection or gastrointestinal obstruction;\n* Known peritoneal adhesions deemed unsuitable for catheter placement;\n* Active bleeding, uncorrected coagulation disorders, or inability to safely interrupt therapeutic anticoagulation;\n* Known hypersensitivity to PX, nab-paclitaxel, or excipients;\n* Pre-existing ≥ Grade 2 peripheral sensory neuropathy;\n* Severe or uncontrolled comorbidities that may increase study risk or interfere with evaluation;\n* Active or severe autoimmune disease, or ongoing systemic immunosuppressive therapy;\n* Positive for HBsAg, anti-HCV, syphilis antibody, or HIV antibody;\n* Psychiatric or cognitive disorders affecting compliance;\n* Any other condition deemed unsuitable by the investigator.",{"count":587,"type":21},22,[235],"To evaluate the safety and tolerability of intraperitoneal PX in combination with nab-paclitaxel in patients with peritoneal metastatic mucinous adenocarcinoma, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).",[591],"Peritoneal (Metastatic) Cancer",[593,594,595,596],"peritoneal adenocarcinoma","PX","nab-paclitaxel","intraperitoneal injection·","2026-03-11",{"date":599,"type":35},"2026-03-13",{"date":601,"type":21},"2026-03-15",{"date":603,"type":21},"2027-12-31",{"name":41,"class":42},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":611,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":613,"enrollmentInfo":614,"targetDuration":4,"studyType":22,"phases":615,"briefSummary":616,"conditions":617,"keywords":619,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":4},"100621650","blended-resources-for-integrated-diabetes-guidance-and-empowerment-100621650","NCT07373379","Blended Resources for Integrated Diabetes Guidance and Empowerment","Effectiveness and Implementation of an AI-Driven Blended Care Model for Type 2 Diabetes Management in Primary Care: A Single-Blind, Cluster Randomized Controlled Trial in Zhangjiagang, China","BRIDGE","Inclusion Criteria:\n\n* Aged 18 to 70 years (inclusive).\n* Glycosylated hemoglobin (HbA1c) level ≥ 6.5%.\n* Resided in the local area for at least 6 months.\n* Capable of using a smartphone to take photos and use the WeChat mini-program.\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Diagnosed with Type 1 diabetes, gestational diabetes, or secondary diabetes.\n* Presence of severe diabetic complications.\n* Received radiotherapy or chemotherapy within the past 6 months.\n* Diagnosed with severe intellectual disabilities, Alzheimer's disease, or other serious psychiatric disorders.\n* Current participation in other research projects that may affect the results of this study.\n* Presence of other severe disabilities or medical conditions deemed unsuitable for participation by the investigators.","70 Years",{"count":542,"type":21},[24],"The goal of this cluster randomized clinical trial is to learn if an AI-enabled blended care model (the BRIDGE program) works to treat type 2 diabetes in adults. It will also learn about the cost-effectiveness and implementation feasibility of this model in primary care settings. The main questions it aims to answer are:\n\nDoes the AI-driven intervention lower HbA1c levels (blood sugar) compared to standard care?\n\nDoes this model improve participants' quality of life, self-management behaviors, and digital literacy?\n\nResearchers will compare the \"Diet-Medicine Companion\" (Shi Yi Ban Lv) mini-program combined with family doctor support to standard community care to see if the blended care model works to manage diabetes.\n\nParticipants will:\n\nUse the \"Diet-Medicine Companion\" mini-program to upload diet photos daily and receive AI feedback for 6 months\n\nReceive periodic guidance and phone reminders from case administrators (family doctors)\n\nComplete questionnaires and blood tests (HbA1c) at baseline, 3 months, and 6 months",[618],"Type 2 Diabetes Mellitus",[618,620,621,622],"digital health","AI","blended care","2026-02-19",{"date":625,"type":35},"2026-02-23",{"date":627,"type":21},"2026-03-01",{"date":629,"type":21},"2026-10-30",{"name":41,"class":42},{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":637,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":540,"minAge":17,"maxAge":4,"enrollmentInfo":639,"targetDuration":4,"studyType":22,"phases":641,"briefSummary":642,"conditions":643,"keywords":645,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":648,"lastUpdatePostDateStruct":649,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":655,"locationsCount":656},"100615607","pregnancy-salt-substitution-trial-for-hypertensive-disorders-of-pregnancy-prevention-preg-salt-100615607","NCT07294807","Pregnancy Salt Substitution Trial for Hypertensive Disorders of Pregnancy Prevention (PREG-Salt)","Effectiveness, Safety, and Cost-effectiveness of Salt Substitution in High-risk Pregnant Women for the Prevention of Hypertensive Disorders of Pregnancy","PREG-Salt","Inclusion Criteria:\n\n1. Singleton pregnancy with a viable fetus at ≤16 weeks of gestation.\n2. Meets at least one of the following criteria (enrolled sequentially):\n\n   1. Systolic Blood Pressure (SBP) ≥130 mmHg and \\\u003C160 mmHg at enrollment, OR current monotherapy with antihypertensive medications such as labetalol or nifedipine (priority enrollment).\n   2. At least one of the following 4 items: advanced maternal age (≥35 years), pre-pregnancy obesity (BMI ≥28 kg\u002Fm²), history of preeclampsia, or pre-existing type 1 or type 2 diabetes.\n   3. At least two of the following 5 items: history of adverse pregnancy outcome (e.g., fetal death, placental abruption, fetal growth restriction), personal history of gestational hypertension or family history of preeclampsia (mother or sister), history of gestational diabetes, obstructive sleep apnea, or pre-pregnancy overweight (BMI 24-28 kg\u002Fm²).\n3. Routinely eats at least two meals per day at home (including meals brought from home).\n4. Able to attend regular antenatal check-ups and is expected to complete the study follow-up.\n5. Provides written informed consent. -\n\nExclusion Criteria:\n\n1. SBP ≥160 mmHg or Diastolic Blood Pressure (DBP) ≥110 mmHg at enrollment.\n2. Conditions or history associated with high uterine tension (e.g., polyhydramnios, macrosomia, hydatidiform mole); autoimmune diseases (e.g., systemic lupus erythematosus, antiphospholipid syndrome).\n3. History of chronic kidney disease, OR any antenatal check-up with a confirmed estimated Glomerular Filtration Rate (eGFR) \\\u003C70 ml\u002Fmin\u002F1.73m², OR dipstick urine protein ≥2+.\n4. Diagnosed hyperkalemia.\n5. History of hypotension or syncope.\n6. A household member who shares meals has a confirmed diagnosis of chronic kidney disease or hyperkalemia.",{"count":640,"type":21},3200,[24],"The PREG-Salt study is to evaluate the effect, safety and cost-effectiveness of low-sodium salt in reducing blood pressure and preventing hypertensive disorders in pregnant women at high risk in China. The study will recruit about 3,200 participants from approximately 100 hospitals across multiple provinces in China. Eligible pregnant women (≤16 weeks of gestation) will be randomly assigned in a 1:1 ratio to the following 2 groups:\n\n1. Salt subsittute(intervention);\n2. Usual salt (control) .\n\nThe intervention will last until delivery. The study employs an adaptive two-phase design. An interim analysis after the first phase (n=400) will inform whether the trial continues into the second phase and if any adjustments to the sample size are needed. The primary outcomes are:\n\nPhase 1: The mean systolic blood pressure across antenatal visits (excluding the last week before delivery).\n\nPhase 2: New-onset hypertensive disorders of pregnancy and related adverse events from randomization to delivery.",[644],"Hypertensive Disorders of Pregnancy",[646,647],"Sodium reduction","Pregnancy disorders","2025-12-19",{"date":650,"type":35},"2025-12-29",{"date":652,"type":21},"2025-12-25",{"date":654,"type":21},"2027-12-25",{"name":41,"class":42},107,""]